Worked on behalf of a major pharmaceutical firm bringing a biosimilar drug to market in the U.S. Despite the expiration of the compound patents, the reference drug manufacturer claimed that the biosimilar infringed on a number of process patents and sought preliminary injunctive relief in multiple jurisdictions, in addition to damages. The plaintiff’s motions for preliminary injunctions were denied.